XENON PHARMACEUTICALS ($XENE) posted quarterly earnings results on Monday, May 12th. The company reported earnings of -$0.83 per share, beating estimates of -$0.93 by $0.10. The company also reported revenue of $7,500,000, beating estimates of $1,129,282 by $6,370,718.
You can see Quiver Quantitative's $XENE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
XENON PHARMACEUTICALS Insider Trading Activity
XENON PHARMACEUTICALS insiders have traded $XENE stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $XENE stock by insiders over the last 6 months:
- IAN MORTIMER (PRESIDENT & CEO) has made 0 purchases and 4 sales selling 55,000 shares for an estimated $2,213,996.
- SHERRY AULIN (Chief Financial Officer) has made 0 purchases and 2 sales selling 18,709 shares for an estimated $770,911.
- GARY PATOU has made 0 purchases and 2 sales selling 4,891 shares for an estimated $200,946.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
XENON PHARMACEUTICALS Hedge Fund Activity
We have seen 80 institutional investors add shares of XENON PHARMACEUTICALS stock to their portfolio, and 99 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 762,209 shares (+10.1%) to their portfolio in Q1 2025, for an estimated $25,572,111
- CAPITAL INTERNATIONAL INVESTORS added 541,520 shares (+21.3%) to their portfolio in Q1 2025, for an estimated $18,167,996
- CITADEL ADVISORS LLC removed 395,201 shares (-54.7%) from their portfolio in Q4 2024, for an estimated $15,491,879
- POINT72 ASSET MANAGEMENT, L.P. removed 383,290 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $15,024,968
- STEMPOINT CAPITAL LP added 375,845 shares (+inf%) to their portfolio in Q4 2024, for an estimated $14,733,124
- FIRST TURN MANAGEMENT, LLC added 359,768 shares (+110.6%) to their portfolio in Q4 2024, for an estimated $14,102,905
- AVIDITY PARTNERS MANAGEMENT LP removed 344,000 shares (-42.1%) from their portfolio in Q4 2024, for an estimated $13,484,800
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
